DelveInsight’s, “Hearing Loss Pipeline Insight 2026” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Hearing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Hearing Loss Pipeline Report @ Hearing Loss Pipeline Outlook Report
Key Takeaways from the Hearing Loss Pipeline Report
Access DelveInsight’s in-depth Hearing Loss Pipeline Analysis for a closer look at promising breakthroughs @ Hearing Loss Clinical Trials and Studies
Hearing Loss Overview
Hearing loss refers to a partial or total inability to hear, which can be present at birth or develop later in life. It can affect one or both ears and is categorized into three main types: conductive hearing loss, caused by issues in the outer or middle ear; sensorineural hearing loss, stemming from damage to the inner ear or auditory nerve; and mixed hearing loss, which involves both conductive and sensorineural components. Hearing loss can manifest through various signs and symptoms, often developing gradually and becoming noticeable over time. Common indicators include difficulty hearing conversations, especially in noisy environments, frequently asking others to repeat themselves, and needing to increase the volume on devices like televisions or radios compared to others. Individuals may also experience muffled sounds, misunderstandings during conversations, and fatigue from concentrating on listening.
Hearing Loss Emerging Drugs Profile
SENS-401 (Arazasetron), Sensorion’s clinical stage drug candidate, is an orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment. Sensorion currently develops SENS-401 in a Phase 2 clinical trial for the prevention of Cisplatin-Induced Ototoxicity and has completed a Phase 2a study to prevent residual hearing loss in patients scheduled for cochlear implantation. SENS-401 has been granted Orphan Drug Designation by the EMA in Europe for the treatment of sudden sensorineural hearing loss, and by the FDA in the US for the prevention of platinum-induced ototoxicity in pediatric population. Currently, the drug is in Phase II/III stage of its clinical trial for the treatment of Hearing Loss.
ACOU085 is a first-in-class, small-molecule, etiology-agnostic otoprotective drug candidate delivered using standard, transtympanic administration of a proprietary, slow-release gel formulation. Ototoxic hearing loss is a typical, severe, and permanent side effect of cisplatin treatment and is a consequence of irreversible damage to the sensory cells in the inner ear, the so-called outer hair cells (OHCs). ACOU085 modulates a biologically validated target, the KCNQ4-encoded Kv7.4 potassium channel of the OHCs, and has demonstrated significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity in preclinical models. Currently, the drug is in Phase II stage of its clinical trial for the treatment of hearing loss.
NS101 is a monoclonal antibody developed by Neuracle Science Co., Ltd., targeting TAFA5, a protein associated with neurodegenerative diseases such as sensorineural hearing loss and Alzheimer’s disease. By modulating TAFA5 activity, NS101 aims to restore neural function and mitigate disease progression. Currently, NS101 is undergoing Phase I/II clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in both healthy volunteers and patients with sudden sensorineural hearing loss.
Get a detailed analysis of the latest innovations in the Hearing Loss pipeline @ Hearing Loss Unmet Needs
Hearing Loss Companies
Sensorion, AudioCure Pharma GmbH, Acousia Therapeutics, Neuracle Science, Regeneron Pharmaceuticals, Sound Pharmaceuticals, PAEAN Biotechnology and others.
Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Hearing Loss Products have been categorized under various Molecule types such as
Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Hearing Loss Market Drivers and Barriers, and Future Perspectives
Scope of the Hearing Loss Pipeline Report
Find out in DelveInsight’s exclusive Hearing Loss Pipeline Report—access it now! @ Hearing Loss Emerging Drugs and Major Companies
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/hearing-loss-pipeline-insight
